Hypertension Effects of Bisoprolol on the reduction of mean arterial pressure and heart rate in male white rats Hypertension and hypertension complicating hypercholesterolemia

Hypertension, Hypercholesterolemia, Arterial Average, Hypercholesterolemia, Bisoprolol.

  • Miming Andika Universitas Fort De Kock
  • Miming Andika Universitas Fort De Kock

Abstract

Hypertension is a cardiovascular disease that often occurs in Indonesia. This is a health problem with a high prevalence, which is 25.8%, according to the 2013 Riskesdas data. People with hypertension also often experience complications with other cardiovascular diseases such as hypercholesterolemia. Beta-blockers are commonly used by people to treat high blood pressure and an excessive heart rate. Experiments on the pharmacological effect of bisoprolol on reducing blood pressure in hypertensive conditions have been carried out by several previous researchers, both preclinically and clinically, but the effect of pathological hypercholesterolemia on the effect of decreasing mean arterial pressure and heart rate has not been established. Therefore, researchers are interested in investigating the effect of decreasing mean arterial pressure and heart rate in hypertensive and hypertensive rats with comorbid hypercholesterolemia. So researchers are interested in conducting research on the effect of bisoprolol on decreasing mean arterial pressure and heart rate in hypertensive male white rats and hypertension complicating hypercholesterolemia in male white rats. In this study, all experimental animals were hypertensive first, then the group with complications of hypercholesterolemia was induced by PTU and high fat diet, then measured using a photometer v5¬+ 5010. Meanwhile, the mean arterial pressure and heart rate were measured using a blood pressure gauge adinstrument NIBP ( Non invasive blood pressure) brand CODA (kent scientific). The data from this study were analyzed by two-way ANOVA. It was found that the administration of bisoprolol with doses of 2.5 mg, 5 mg and 10 mg significantly decreased mean arterial pressure and heart rate (p 0.05). And the 10 mg dose was the most effective in reducing the mean arterial pressure and heart rate in hypertensive male white rats and hypertension complicating hypercholesterolemia. And there is a difference in the decrease in mean arterial pressure and heart rate in male white rats with hypertension, the decrease is greater than in male white rats with hypertension complicated by hypercholesterolemia.

References

Anggraini, D.A, dkk. 2009, Faktor-Faktor yang Berhubungan dengan Kejadian Hipertensi pada Pasien yang Berobat di Poliklinik Dewasa Puskesmas Bangkinang Periode Januari Sampai Juni 2008.
Anies. 2015. Kolesterol dan penyakit jantung koroner. Yogyakarta: Ar-Ruzz Media.
Baker, P. (1987). Hypertension and its treatment. The Pharm. Journal, 12-14.
Bousquet, P. & Feldman, J. (1987). The blood pressure effects of alpha-adrenoceptor antagonists injected in the medullary site of action of clonidine: the nucleus reticularis lateralis. Life Sci. 40: 1045-1052.
Brashers, V. L. 2003. Aplikasi klinis patofisiologi: pemeriksaan dan manajemen.(Edisi ke-2). Penerjemah: Y. Kuncara. Jakarta: Penerbit Buku Kedokteran EGC.
Chamienia, A.L., and Johns, E.J. (1996). The cardiovascular and renal functional responses to 5HT1A receptor agonist, flesinoxan in two rats models of hypertension. Br. J. Pharmacol. 118: 1891-1898.
Depkes RI, 2001, Survei Kesehatan Rumah Tangga tahun 2001. Jakarta: Departement Kesehatan RI.
Depkes RI. Farmakope Indonesia (Edisi V). Jakarta, Indonesia: DepartemenKesehatan; 2014.
Dipiro JT, Talbert RL, Yee GC, Matzke GR, Weels BG, Posey LM. Pharmacotherapy A Pathophysiologic Approach (7th Edition). USA: The McGraw-Hill Companies; 2008.
Dipiro, J.T, Dipiro, C. V, Schwinghammer, T.L, Wells, B.G (2015), Pharmacotherapy Handbook : Ninth Edition MC Graw Hill Education, London
Dipiro, J. T., C. V Dipiro., T. L Schwinghammer., B. G. Wells, 2012. Pharmacotherapy Handbook: Ninth Edition.MC Graw Hill Education: London.
Ganiswara, S. G. 1995. Farmakologi dan Terapi (Edisi 4). Jakarta: Fakultas Kedokteran Universitas Indonesia.
Ganong, F.W. (1999). A Lange Medical Book. Review of Medical Physiology. 19th ed. Edited by Appleton and Lange. New Jersey. America.
Gilman, A. G., Hardman, J. G., and limbird, L. E. Goodman & Gilman’s The Pharmacological Basis of Therapeutics, 9th ed. The MvGraw-Hill Co. Inc : New York. 1996.
Guyton, A.C. (1987). Human Physiology and Mechanisms of Disease, 4th ed W.B. Saunders Company, Philadelphia.
Guyton, A.C. (1991). Textbook of Medical Physiology, 8th ed., W.B. Saunders Company, Philadelphia.
Hall, J.E., Guyton, A.C., and Brands, M.W., (1996). Pressure-volume regulation in hypertension, Kidney International, Vol 49, Suppl. 55, pp. S-35 - S-41.
Julius, S., 2008, Clinical Implications of Pathophysiologic Changes in the Midlife Hypertensive Patients. American Heart Journal, 122: 886-891.
Kowalski, R., 2010, Terapi Hipertensi. Terjemahan: Rani S. Bandung: QanitaZulkeflie, NASB 2011
Mescher AL. Histologi Dasar Junquiera: Teks & Atlas (Edisi 12). Jakarta,
Indonesia: EGC; 2011
Notoadmodjo, 2010, PromosiKesehatan dan IlmuPerilaku. Jakarta: Rineka Cipta.
Oktora R., 2007, Gambaran Penderita Hipertensi Yang Dirawat Inap di Bagian Penyakit Dalam RSUD Arifin Achmad Pekanbaru Periode Januari Sampai Desember 2005, Skripsi, FK UNRI, hal 41-42.
PodmajaUday kumar, (2011). Textbook of Medical Pharmacology, 3th ed., W.B. Saunders Company, Philadelphia.
Prabha, P. S., U. N. Das, R. Koratkar, P. S.Sagar, dan G. Ramesh. 1990. free radical generation, lipid peroxidation and essensial fatty acids in uncontrolled essential hypertension. Prostaglandins Leukot Eaaent Fatty Acids. 41(1), 27-33.
Sawicka et al. 2011. Hypertension-The Silent Killer. Journal of Pre-Clinical and Clinical Research. Vol 5 No 2. 43-46
Sarastini, N., 2008, Faktor-faktor yang berhubungan dengan kejadian hipertensi pada masyarakat usia 30 tahun keatas depok tahun 2008. Journal of hypertension factor research, 21 (2), 1-8, doi : 486/nejmoa 3291/full.
Silbernagl, S. 2007. In: Silbernagl, S., Lang, F. editor. Teks dan Atlas Berwarna Patofisiologi. Jakarta : EGC
The Seventh Report of the Joint National Committee. (2004).Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. National Institutes of Health National Heart, Lung, and Blood Institute: London
Vogel, H. G. 2002. Drug discovery and evaluations pharmacological assays. (2th
Edition). Germany: Springer.
Wade, A Hwheir, D N Cameron, A., 2003, Using a Problem Detection Study (PDS)to Identify and Compare Health Care Privider and Consumer Views of Antihypertensive therapy. Journal of Human Hypertension, Jun Vol 17 Issue 6,p397
World Health Organization (WHO), 2005, Risk Factor. Available from : http://www.who.int/cardiovascular_ diseases/en/cvd_atlas_03_risk_fac
Published
2022-06-28
pdf (Bahasa Indonesia)
Abstract views: 99
downloads: 72